文献速递腹部CTMR

LI-RADS 2018版LR-5与修订版LI-RADS诊断肝细胞癌的个体参与者数据Meta分析

Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis.
PubMed 文献 · Radiology · 2023-01-01

该个体参与者数据Meta分析纳入24项研究、3840例患者和4727个观察,比较LI-RADS v2018 LR-5与修订版rLI-RADS rLR-5诊断肝细胞癌的性能;rLR-5敏感度高于LR-5(70.6% vs 61.3%,P < .001),阳性预测值相似(90.7% vs 92.3%,P = .55)。

要点

  • rLR-5诊断肝细胞癌的敏感度高于LR-5,阳性预测值保持相似。
  • rLR-5敏感度70.6%,LR-5为61.3%;两者PPV分别为90.7%和92.3%。
  • 低偏倚风险研究中rLR-5敏感度仍高于LR-5,PPV相似。

核心结论

  • rLR-5识别肝细胞癌的敏感度高于LR-5,同时维持约90%或以上的可比阳性预测值,与原始rLI-RADS研究结果一致。

研究设计与样本

  • 个体参与者数据Meta分析,检索2014年1月至2022年1月多个数据库,纳入24项评估CT或MRI上任意版本LI-RADS诊断肝细胞癌性能的研究,共3840例患者、4727个观察,采用广义线性混合模型计算并比较敏感度与阳性预测值。

关键影像表现/征象

  • 观察病灶大小中位数为19 mm(IQR,11-30 mm)。
  • 观察按主要特征及LI-RADS v2018或rLI-RADS分类进行归类。

诊断标准与关键数值

  • rLR-5敏感度70.6%(95% CI:60.7,78.9),LR-5敏感度61.3%(95% CI:45.9,74.7),P < .001。
  • rLR-5阳性预测值90.7%,LR-5阳性预测值92.3%,P = .55。
  • 低偏倚风险研究(n = 4;1031个观察)中,rLR-5敏感度72.3%(95% CI:63.9,80.1),LR-5敏感度66.9%(95% CI:58.2,74.5),P = .02。
  • 低偏倚风险研究中,rLR-5阳性预测值83.1%,LR-5阳性预测值88.7%,P = .47。

临床应用与阅片要点

  • 采用Quality Assessment of Diagnostic Accuracy Studies version 2评估研究偏倚风险。
  • rLR-5在保持阳性预测值约90%或以上的同时提高了敏感度,与原始rLI-RADS研究结果一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background A simplification of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 (v2018), revised LI-RADS (rLI-RADS), has been proposed for imaging-based diagnosis of hepatocellular carcinoma (HCC). Single-site data suggest that rLI-RADS category 5 (rLR-5) improves sensitivity while maintaining positive predictive value (PPV) of the LI-RADS v2018 category 5 (LR-5), which indicates definite HCC. Purpose To compare the diagnostic performance of LI-RADS v2018 and rLI-RADS in a multicenter data set of patients at risk for HCC by performing an individual patient data meta-analysis. Materials and Methods Multiple databases were searched for studies published from January 2014 to January 2022 that evaluated the diagnostic performance of any version of LI-RADS at CT or MRI for diagnosing HCC. An individual patient data meta-analysis method was applied to observations from the identified studies. Quality Assessment of Diagnostic Accuracy Studies version 2 was applied to determine study risk of bias. Observations were categorized according to major features and either LI-RADS v2018 or rLI-RADS assignments. Diagnostic accuracies of category 5 for each system were calculated using generalized linear mixed models and compared using the likelihood ratio test for sensitivity and the Wald test for PPV. Results Twenty-four studies, including 3840 patients and 4727 observations, were analyzed. The median observation size was 19 mm (IQR, 11-30 mm). rLR-5 showed higher sensitivity compared with LR-5 (70.6% [95% CI: 60.7, 78.9] vs 61.3% [95% CI: 45.9, 74.7]; P < .001), with similar PPV (90.7% vs 92.3%; P = .55). In studies with low risk of bias (n = 4; 1031 observations), rLR-5 also achieved a higher sensitivity than LR-5 (72.3% [95% CI: 63.9, 80.1] vs 66.9% [95% CI: 58.2, 74.5]; P = .02), with similar PPV (83.1% vs 88.7%; P = .47). Conclusion rLR-5 achieved a higher sensitivity for identifying HCC than LR-5 while maintaining a comparable PPV at 90% or more, matching the results presented in the original rLI-RADS study. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Sirlin and Chernyak in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Goins SM, Jiang H, van der Pol CB, et al. Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis. Radiology. 2023. PMID: 38112549. doi:10.1148/radiol.231656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。